Corindus Vascular Robotics sees significant customer growth and omentum on path to ACC14

Waltham, MA – March 26, 2014 (Booth # 1343) – Corindus Vascular Robotics, the leader in precision vascular robotics, will showcase its FDA-cleared CorPath System at the upcoming American College of Cardiology (ACC) annual meeting, March 29 – 31 in Washington, D.C. The CorPath is the first medical device to bring robotic precision and accuracy to coronary angioplasty to help optimize clinical outcomes. Corindus representatives will be onsite to conduct demos of the CorPath System and answer questions about the significant advantages in procedure precision and improvements in clinical outcomes made possible by robotics in the cath lab.
 
As a leader in the robotic space, Corindus has seen 300 percent growth in customer installs since spring of 2013. In late-2013, Corindus successfully installed a CorPath system at Orlando Regional Medical Center (ORMC), the first in Florida, as well as the first CorPath in a hospital within the Carolinas, and the second system in New York State. The adoption of the CorPath system continues to grow steadily and several customers now have two or more CorPath systems installed. CorPath systems are installed across the United States with several more pending within the next few months.
 
“The basic technique used in coronary angioplasties has remained largely the same since the first stent procedure was performed in 1986,” said David Handler, President and CEO of Corindus Vascular Robotics. “The introduction of robotic-assisted systems offers interventional cardiologists improvements in their ability to perform the procedure with enhanced precision, seated in a radiation-protected cockpit. We have found physicians to be extremely receptive to this technology due to the precision and effectiveness of stent placement – and their positive feedback is a testament to the incredible growth we’ve seen over the last year.”
 
Most recently, Corindus announced a partnership with Sanford Health and The Leona M. and Harry B. Helmsley Charitable Trust to launch a technical feasibility investigation for a remote robotics program. The program is intended to empower an interventional cardiologist at a major center to robotically control the movement of interventional devices at a remote facility.
 
“We are committed to pioneering a positive change in the delivery of heart care and making a significant impact for patients,” continued Handler.
 
###
 
About Corindus Vascular Robotics
Corindus Vascular Robotics is the global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company’s FDA-cleared CorPath® 200 System is the first medical device that offers interventional cardiologists PCI procedure control from an interventional cockpit. With the CorPath System, Corindus brings robotic precision to PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications through improper stent placement. Corindus stands behind its technology with a “One Stent Promise,” offering a $1,000 credit to hospitals that use two or more stents per lesion in PCI procedures performed with the CorPath System. For additional information, visit www.corindus.com.